Reynolds v. EzriCare LLC

Background

Milton and Danae Reynolds alleged that contaminated EzriCare Artificial Tears caused Milton Reynolds to develop a Pseudomonas aeruginosa infection and ultimately lose sight in his right eye. Milton Reynolds purchased two bottles through Amazon and used them in California. The plaintiffs sued EzriCare, EzriRx, Global Pharma Healthcare Private Limited, and Amazon on claims including strict product liability, negligence and gross negligence, negligent failure to warn, negligent failure to recall, breach of implied warranty, fraud, and loss of consortium.

Global designed, manufactured, and packaged the eye drops in India. Aru Pharma imported and distributed them to companies in the United States, including EzriCare. EzriCare designed the exterior label, marketed the product as EzriCare Artificial Tears, and listed it for sale on online platforms, including Amazon. The opinion states that the Centers for Disease Control and Prevention reported an outbreak linked to the product and that its investigation was ongoing.

EzriRx’s Motion to Dismiss for Lack of Personal Jurisdiction

The court denied EzriRx’s motion. Personal jurisdiction is a court’s authority over a defendant. The court applied the test for specific personal jurisdiction, which asks whether the defendant directed activities toward the forum state, whether the claims arose from or related to those activities, and whether exercising jurisdiction would be reasonable.

The plaintiffs alleged that EzriRx participated in marketing and distributing the eye drops and called California pharmacies to market and sell products. The court found those allegations sufficient at this stage to show that EzriRx purposefully directed conduct toward California. The plaintiffs also alleged that Milton Reynolds purchased, used, and was injured by the eye drops in California. The court concluded that his injuries related closely enough to EzriRx’s California contacts and noted that EzriRx offered no reason why jurisdiction would be unreasonable.

EzriCare’s Motion to Dismiss

The court granted EzriCare’s motion to dismiss in part and denied it in part. It denied the motion as to the claims based on alleged lumping together of defendants, manufacturing defect, design defect, strict-liability failure to warn, negligent failure to warn, breach of implied warranty, negligence, and loss of consortium. The court granted the motion as to fraud and negligent failure to recall.

The court held that the complaint adequately identified EzriCare’s alleged role as an apparent manufacturer and alleged that EzriCare packaged, labeled, marketed, advertised, supplied, distributed, and sold the product. The complaint plausibly alleged manufacturing and design defects because the product allegedly caused infection and blindness. It also plausibly alleged that EzriCare failed to warn about contamination risks associated with preservative-free eye drops in a multi-use bottle.

The court found the implied-warranty claim adequately pleaded because eye drops that cause infection and blindness allegedly are not fit for their ordinary purpose. The negligence claim also survived because the plaintiffs alleged that EzriCare had a duty to test the product for safety and sterility and breached that duty. Because most of the other claims survived, the court declined to dismiss Danae Reynolds’s derivative loss-of-consortium claim.

The fraud claim was dismissed because the plaintiffs did not identify specific statements or conduct by EzriCare or provide the required details about what was false or misleading. The negligent-failure-to-recall claim was dismissed because the plaintiffs did not allege when EzriCare knew or should have known about the connection between the product and the bacterial infections. The court gave the plaintiffs leave to amend both dismissed claims and directed them to file an amended complaint by November 20, 2023.

EzriCare’s Motion to Stay

The court denied EzriCare’s motion to stay in its entirety. A stay temporarily pauses litigation. EzriCare argued that a stay was needed because Aru Pharma and Global were necessary parties, because Global had not yet been served, and because a regulatory agency should address issues related to the product first.

The court concluded that Aru Pharma and Global were permissive rather than necessary parties. It also found that EzriCare had not shown what evidence Aru Pharma possessed, that discovery from Aru Pharma would be unavailable, or that proceeding would cause the asserted prejudice. The court emphasized that a stay would hardship the plaintiffs, including Milton Reynolds, who was blind in one eye. The court also declined to stay the case based on the primary-jurisdiction doctrine because the plaintiffs’ claims focused on Milton Reynolds’s injury and whether the purchased eye drops caused it, matters the court found suitable for judicial resolution.

Amazon’s Motion to Dismiss

The court denied Amazon’s motion to dismiss the implied-warranty-of-merchantability claim. Amazon argued that it was not a retail seller under the Song-Beverly Consumer Warranty Act and that there was no required direct relationship, or vertical privity, between Amazon and Milton Reynolds under California’s commercial code.

The court found that the plaintiffs plausibly alleged Amazon had taken part in selling and handling the eye drops, including by storing the product, facilitating communications, and processing returns. The court also found that the record did not establish as a matter of law that EzriCare alone was the seller. Because California courts had not finally resolved whether Amazon could be liable for an implied-warranty claim involving third-party sellers, the court declined to decide the issue without further discovery and a fuller record.

Disposition

In Reynolds v. EzriCare LLC, Judge Jacquelyn Scott Corley denied EzriRx’s motion to dismiss for lack of personal jurisdiction; granted EzriCare’s motion to dismiss in part and denied it in part; denied EzriCare’s motion to stay; and denied Amazon’s motion to dismiss. The fraud and negligent-failure-to-recall claims against EzriCare were dismissed, with leave to amend. All other claims against EzriCare survived at this stage.